

# Contents

---

<b>1</b>	<b>What is Pharmacology?</b>	<b>1</b>
	<i>Humphrey Rang</i>	
1.1	Introduction	1
1.2	Origins and Antecedents	2
1.3	The Emergence of Pharmacology as a Science	4
1.4	Receptors and Drug Targets	8
1.5	Pharmacology in Drug Discovery	9
1.6	Pharmacology Today	12
	References	13
<b>2</b>	<b>The Pharmacological Analysis of Drug Activity in Receptor Systems</b>	<b>14</b>
	<i>Terry Kenakin</i>	
2.1	Introduction	14
2.2	Data-driven Analysis	17
2.3	Characterizing Agonist Activity	20
2.4	Antagonism	24
2.5	Allosteric Modulation	27
2.6	Assignment of Receptor Models to Characterize Activity	31

---

Pharmacology for Chemists: Drug Discovery in Context  
Edited by Raymond Hill, Terry Kenakin and Tom Blackburn  
© The Royal Society of Chemistry 2018  
Published by the Royal Society of Chemistry, [www.rsc.org](http://www.rsc.org)

---

2.7	Biochemical Binding Studies	39
2.8	Kinetic Studies of Drug Function	41
2.9	Conclusions	43
	References	43

---

<b>3</b>	<b>Structure-based Drug Discovery and Advances in Protein Receptor Crystallography</b>	<b>45</b>
	<i>Miles Congreve and Fiona H. Marshall</i>	
3.1	Introduction	45
3.2	Principles and Practice of Structure-based Design	48
3.3	New Techniques in Membrane Protein Crystallography	51
3.4	Structural Biology of G Protein-coupled Receptors	54
3.5	Structure-based Drug Discovery Applied to Protein Classes	58
3.6	Conclusions	67
	Acknowledgements	67
	References	67

---

<b>4</b>	<b>Actions of Drugs on the Autonomic Nervous System</b>	<b>73</b>
	<i>Thomas P. Blackburn</i>	
4.1	Introduction	73
4.2	Post- and Presynaptic Receptors	81
4.3	Anatomy, Physiology and Pharmacology of Cholinergic Neurotransmission	82
4.4	Cholinergic Receptors and Receptor Subtypes	84
4.5	Noradrenergic Receptors and Receptor Subtypes	99
	References	127

---

<b>5</b>	<b>Actions of Drugs on The Brain and CNS Disorders</b>	<b>130</b>
	<i>Thomas P. Blackburn</i>	
5.1	Function of Various Brain Regions	130
5.2	The Development of Psychotropic Drugs (1950–2010)	130
5.3	CNS Disorders: Anxiety, Depression, Bipolar Disorders and Schizophrenia	132
5.4	Types of Depression	135
5.5	CNS Clinical Trial Issues	145
5.6	Antidepressants	150
5.7	Schizophrenia	166
5.8	Antiepileptics	170
5.9	Sedatives and Hypnotics	174
5.10	Psychostimulants and Psychotomimetic	178
5.11	Anaesthetics	179
5.12	Neurochemistry and Physiology of Neurotransmitters in the Central Nervous System	185
5.13	Dopamine and Parkinson's Disease and Huntington's Chorea	211
	References	215

---

<b>6</b>	<b>Actions of Drugs on the Cardiovascular and Renal System</b>	<b>221</b>
	<i>Thomas P. Blackburn</i>	
6.1	Anatomy and Physiology of the Heart	221
6.2	Cardiovascular Physiology and Pharmacology	223
6.3	Hypertension	224
6.4	Antihypertensive Drugs	231
6.5	Vasodilator Drugs that Affect Noradrenergic Neurons	236
6.6	Atherosclerosis and Lipoprotein Metabolism	239
6.7	Antiarrhythmic Drugs and Ischemic Heart Disease	252
6.8	Ischemic Heart Disease	258
6.9	Haemostasis and Thrombosis	263
6.10	Fibrinolysis (Thrombolysis)	269
6.11	Heart Failure	270
6.12	Kidney and Urinary System	278
	References	290

---

<b>7</b>	<b>Actions of Drugs in the Gastrointestinal Tract</b>	<b>292</b>
	<i>Gareth J. Sanger</i>	
7.1	Introduction	292
7.2	Protection and Healing of the Oesophagus and Stomach	293
7.3	Inhibition and Prevention of Nausea and Vomiting	296
7.4	Stimulation of Gastric Motility and Emptying	301
7.5	Treatment of Chronic Constipation, Megacolon and Intestinal Pseudo-obstruction	304
7.6	Inhibition of Diarrhoea	309
7.7	Functional Bowel Disorders	309
7.8	Factors that Could Change the Landscape	312
	Further Reading	312

---

<b>8</b>	<b>The Future of ADME in Drug Design and Development</b>	<b>316</b>
	<i>Phil Jeffrey and Scott Summerfield</i>	
8.1	Introduction	316
8.2	Understanding ADME	318
8.3	Screening Assays	320
8.4	Dose	328
	References	336

---

<b>9</b>	<b>Predictive Strategies for ADRs – Biomarkers and <i>In Vitro</i> Models</b>	<b>343</b>
	<i>Dan Antoine, Neil French and Munir Pirmohamed</i>	
9.1	Introduction	343
9.2	Drug-induced Kidney Injury (DIKI)	345
9.3	Drug-induced Liver Injury (DILI)	349
9.4	Predictive Strategies for ADRs – Pharmacogenomics	367
	References	370

---

<b>10</b>	<b>From Bench to Bedside: The First Studies of a New Molecule in Man</b>	<b>379</b>
	<i>Kate Darwin, Liv Thomsen and Malcolm Boyce</i>	
10.1	Introduction	379
10.2	Preparing for Early Clinical Studies	384
10.3	First in Human (FIH) Studies	399
10.4	Conclusions	415
	Acknowledgements	415
	References	415
<hr/>		
<b>11</b>	<b>Nonclinical Safety Assessment in Drug Development</b>	<b>418</b>
	<i>Shayne Gad</i>	
11.1	Introduction	418
11.2	Stages and Components of Nonclinical Safety Assessment	420
11.3	Strategies for Development	421
11.4	Do Only What You Must	422
11.5	Minimize the Risk of Subsequent Failure	422
11.6	What You Need to Know to Start	423
11.7	Strategies for Development	423
11.8	The Stages	424
11.9	ICH Requirements: The Global General Case	426
11.10	The First Rule	426
11.11	Toxicity Testing: Traditional Pharmaceuticals	428
11.12	Common Mistakes	428
11.13	Toxicity Testing of Pharmaceuticals – The General Approach	429
11.14	Developmental and Reproductive Toxicity Studies	433
11.15	Genetic Toxicity Assessment	434
11.16	Safety Pharmacology Studies	436
11.17	Toxicity Testing: Biotechnology Products	437
11.18	Special Cases	440
11.19	Imaging Agents (a Case of Direct to FIM Trials)	447
11.20	Excipients	448
11.21	Nonclinical Safety Evaluation Studies Conducted to Support Continued Clinical Development	451

11.22	Impurities, Degradants, and Residual Solvents	453
11.23	Residual Metals and Metal Catalysts	461
11.24	Safety Assessment of Metabolites	464
11.25	Local Tissue Tolerance	467
11.26	Supporting Marketing Applications	468
11.27	Nontraditional (Other than NDA/505b (1)) Approval Routes and Requirements	468
11.28	Special Therapeutic Category and Route of Administration Cases	471
11.29	Specific Therapeutic Classes	471
11.30	Oncology Drugs	471
11.31	Nonclinical Data Evaluation to Support Clinical Trial Design	475
11.32	Routes and Regimens Other than Oral and Daily References	479

---

## 12 Predicting Dose and Selective Efficacy in Clinical Studies from Preclinical Experiments: Practical Pharmacodynamics 483

*R. G. Hill*

12.1	Introduction	483
12.2	How to Ensure that Robust Data is Generated from Studies Performed <i>In Vivo</i>	484
12.3	Experiments to Target Measures of Efficacy or Surrogate Endpoints	487
12.4	Species Selectivity and the Predictive Value of Studies in Animals	490
12.5	The Importance of Imaging Studies in Drug Discovery	497
12.6	Experiments to Explain Unexpected Events Seen in Clinical Studies	498
12.7	Reproducibility of Animal Experiments	499
	Acknowledgements	499
	References	499

## Subject Index 504